Acuitas Investments LLC Sells 51,937 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

Acuitas Investments LLC decreased its holdings in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 30.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 121,258 shares of the company’s stock after selling 51,937 shares during the period. Acuitas Investments LLC’s holdings in Sera Prognostics were worth $725,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Perigon Wealth Management LLC bought a new position in shares of Sera Prognostics during the fourth quarter valued at approximately $509,000. Vanderbilt University purchased a new stake in shares of Sera Prognostics in the fourth quarter valued at approximately $284,000. Resource Consulting Group Inc. purchased a new stake in shares of Sera Prognostics in the fourth quarter valued at approximately $265,000. Finally, CWM LLC purchased a new stake in shares of Sera Prognostics in the fourth quarter valued at approximately $242,000. Institutional investors own 54.64% of the company’s stock.

Insider Activity

In other news, insider Paul Kearney sold 4,984 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $8.03, for a total transaction of $40,021.52. Following the completion of the sale, the insider now owns 160,066 shares in the company, valued at approximately $1,285,329.98. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Sera Prognostics news, insider Paul Kearney sold 4,984 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $8.03, for a total transaction of $40,021.52. Following the sale, the insider now directly owns 160,066 shares of the company’s stock, valued at approximately $1,285,329.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Benjamin Jackson sold 5,665 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $8.03, for a total value of $45,489.95. Following the sale, the general counsel now directly owns 152,035 shares in the company, valued at $1,220,841.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 141,335 shares of company stock worth $1,255,192. Insiders own 15.60% of the company’s stock.

Sera Prognostics Stock Up 1.6 %

Shares of NASDAQ SERA traded up $0.17 during trading hours on Friday, reaching $10.51. The stock had a trading volume of 30,557 shares, compared to its average volume of 223,256. The business’s fifty day moving average price is $9.42 and its two-hundred day moving average price is $6.12. Sera Prognostics, Inc. has a 52-week low of $1.52 and a 52-week high of $11.32.

Sera Prognostics (NASDAQ:SERA) last posted its earnings results on Wednesday, March 20th. The company reported ($0.25) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.25). The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.10 million. Sera Prognostics had a negative return on equity of 45.74% and a negative net margin of 11,843.79%. Sell-side analysts expect that Sera Prognostics, Inc. will post -0.94 earnings per share for the current year.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.